Correction to: Characterization of lsa(D), a Novel Gene Responsible for Resistance to Lincosamides, Streptogramins A, and Pleuromutilins in Fish Pathogenic Lactococcus garvieae Serotype II by Shi Y-Z, et al. Microb Drug Resist 2020 [Epub Ahead of Print]; DOI: 10.1089.mdr.2020.0218.

Abstract

Microbial Drug ResistanceAhead of Print Open AccessCorrection to: Characterization of lsa(D), a Novel Gene Responsible for Resistance to Lincosamides, Streptogramins A, and Pleuromutilins in Fish Pathogenic Lactococcus garvieae Serotype II by Shi Y-Z, et al. Microb Drug Resist 2020 [Epub Ahead of Print]; DOI: 10.1089.mdr.2020.0218.Published Online:23 Dec 2020https://doi.org/10.1089/mdr.2020.0218.correxAboutSectionsView articleSupplemental MaterialPDF/EPUBView Supplemental Data Permissions & CitationsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleCorrections are needed for the article entitled, Characterization of lsa(D), a Novel Gene Responsible for Resistance to Lincosamides, Streptogramins A, and Pleuromutilins in Fish Pathogenic Lactococcus garvieae Serotype II, by Shi, Y.-Z., Yoshida, T., Fujiwara, A., and Nishiki, I. [Epub Ahead of Print]; DOI: 10.1089/mdr.2020.0218. The article contained errors in minimum inhibitory concentrations (MICs) of virginiamycin M1 (VGM) antibiotic. The contents of Tables 2 and 3, and the accompanying text should be revised as follows:Table 2. Minimum Inhibitory Concentrations of Antimicrobials and lsa(D) Genetic Variants in Lactococcus garvieae Serotype IIStrainMIC (μg/mL)LSAP phenotypeaVariation in Lsa(D)bLCMCMVGMTIMEM233 at amino acid mutation positionLSAP-sensitive phenotype strain 1220610.20.056.253.130.05SPTC (TAG) IJF4270.20.056.250.390.05SPTC (TAG) KGLA15120.20.056.250.390.05SPTC (TAG) KGLA16020.20.056.250.390.05SPTC (TAG) Δlsa(D)[pMX1::allele of lsa(D)]0.20.056.250.780.05SPTC (TAG)LSAP-resistant phenotype strain KGLA15042512.51004000.05RW (TGG) KGLA15192512.51004000.05RW (TGG) KGLA15222512.51004000.05RW (TGG) KGLA152750251002000.05RW (TGG)Laboratory-induced resistant mutant 122061-R50251002000.05RY (TAT) IJF427-R5012.51002000.05RW (TGG) KGLA1512-R251.5625250.05RQ (CAG) KGLA1602-R256.25501000.05RY (TAT) Δlsa(D)[pMX1::allele of lsa(D)]-R10012.51002000.05RY (TAT)aLSAP: L (LCM and CM), SA (VGM), and P (TIM).bAmino acid variations in Lsa(D) were confirmed by sequencing all mutants.CM, clindamycin; EM, erythromycin; LCM, lincomycin; MIC, minimum inhibitory concentration; PTC, premature termination codon; Q, glutamine; R, resistance; S, sensitive; TIM, tiamulin; VGM, virginiamycin M1; W, tryptophan; Y, tyrosine.Table 2. Minimum Inhibitory Concentrations of Antimicrobials and lsa(D) Genetic Variants in Lactococcus garvieae Serotype IIStrainMIC (μg/mL)LSAP phenotypeaVariation in Lsa(D)b233 at amino acid mutation positionLCMCMVGMTIMEMLSAP-sensitive phenotype strain1220610.20.050.783.130.05SPTC (TAG)IJF4270.20.051.560.390.05SPTC (TAG)KGLA15120.20.051.560.390.05SPTC (TAG)KGLA16020.20.051.560.390.05SPTC (TAG)Δlsa(D)[pMX1::allele of lsa(D)]0.20.051.560.780.05SPTC (TAG)LSAP-resistant phenotype strainKGLA15042512.5254000.05RW (TGG)KGLA15192512.512.54000.05RW (TGG)KGLA15222512.512.54000.05RW (TGG)KGLA15275025252000.05RW (TGG)Laboratory-induced resistant mutant122061-R5025252000.05RY (TAT)IJF427-R5012.5252000.05RW (TGG)KGLA1512-R251.563.13250.05RQ (CAG)KGLA1602-R256.256.251000.05RY (TAT)Δlsa(D)[pMX1::allele of lsa(D)]-R10012.5252000.05RY (TAT)aLSAP: L (LCM and CM), SA (VGM), and P (TIM).bAmino acid variations in Lsa(D) were confirmed by sequencing all mutants.CM, clindamycin; EM, erythromycin; LCM, lincomycin; MIC, minimum inhibitory concentration; PTC, premature termination codon; Q, glutamine; R, resistance; S, sensitive; TIM, tiamulin; VGM, virginiamycin M1; W, tryptophan; Y, tyrosine.Table 3. The Minimum Inhibitory Concentrations for Lactococcus garvieae Serotype II KGLA1504, Δlsa(D), and Each Complementary Strain, Δlsa(D)[pMX1], Δlsa(D)[pMX1::lsa(D)], and Δlsa(D)[pMX1::allele of lsa(D)]StrainMIC (μg/mL)Resistance-related gene detectedaLSAP phenotypebLCMCMVGMTIMEMSPCKGLA15042512.51002000.05200lsa(D)RΔlsa(D)0.390.056.250.780.05200—SΔlsa(D)[pMX1]0.20.056.250.780.05>500spcSΔlsa(D)[pMX1::lsa(D)]2512.51001000.05>500spc, lsa(D)RΔlsa(D)[pMX1::allele of lsa(D)]0.390.056.250.780.05>500spc, allele of lsa(D)SaResistance-related genes were detected by PCR amplification with gene-specific primers listed in Supplementary Table S1.bLSAP: L (LCM and CM), SA (VGM), and P (TIM).PCR, polymerase chain reaction; SPC, spectinomycin.Table 3. The Minimum Inhibitory Concentrations for Lactococcus garvieae Serotype II KGLA1504, Δlsa(D), and Each Complementary Strain, Δlsa(D)[pMX1], Δlsa(D)[pMX1::lsa(D)], and Δlsa(D)[pMX1::allele of lsa(D)]StrainMIC(μg/mL)Resistance-related gene detectedaLSAP phenotypebLCMCMVGMTIMEMSPCKGLA15042512.5252000.05200lsa(D)RΔlsa(D)0.390.051.560.780.05200-SΔlsa(D)[pMX1]0.20.051.560.780.05>500spcSΔlsa(D)[pMX1::lsa(D)]2512.5251000.05>500spc, lsa(D)RΔlsa(D)[pMX1::allele of lsa(D)]0.390.051.560.780.05>500spc, allele of lsa(D)SaResistance-related genes were detected by PCR amplification with gene-specific primers listed in Supplementary Table S1.bLSAP: L (LCM and CM), SA (VGM), and P (TIM).PCR, polymerase chain reaction; SPC, spectinomycin.Original text, Page 3, lines 1–4 of the 1st paragraph:“CM, EM, and VGM were purchased from LKT Laboratories, Inc. (Minnesota), Nacalai Tesque, Inc. (Kyoto, Japan), andCosmo Bio Co., Ltd. (Tokyo, Japan), respectively.”Should be corrected to:“CM, EM, and VGM were purchased from LKT Laboratories, Inc. (Minnesota), Nacalai Tesque, Inc. (Kyoto, Japan), andSigma-Aldrich Co. LLC. (Missouri, USA), respectively.”Original Table 2The corrected MICS of VGM of the strains in Table 2 was shown below.Original text, Page 5, lines 8–9 of 3rd paragraph:‘’and a 16-fold decrease in the MIC of VGM (from 100 to 6.25 μg/mL). ‘’Should be corrected to:‘’and a 16-fold decrease in the MIC of VGM (from25to1.56μg/mL). ‘’Original text, Page 5, lines 18–19 of 3rd paragraph:‘’and a 16-fold increase in the MIC of VGM (from 6.25 to 100 μg/mL). ‘’Should be corrected to:‘’and a 16-fold increase in the MIC of VGM (from1.56to25μg/mL). ‘’Original text, Page 5, lines 14–15 of 3rd paragraph:‘’and ≥4-fold increase in the MIC of VGM (from 6.25 to 25–100 μg/mL).‘’Should be corrected to:‘’and ≥2-fold increase in the MIC of VGM (from0.78-1.56to3.13–25μg/mL). ‘’Page 7, Table 3:The corrected MICs of VGM of the five strains in Table 3 was shown below.The online version of the article has been corrected. The authors apologize for these errors.FiguresReferencesRelatedDetails Volume 0Issue 0 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Correction to: Characterization of lsa(D), a Novel Gene Responsible for Resistance to Lincosamides, Streptogramins A, and Pleuromutilins in Fish Pathogenic Lactococcus garvieae Serotype II by Shi Y-Z, et al. Microb Drug Resist 2020 [Epub Ahead of Print]; DOI: 10.1089.mdr.2020.0218..Microbial Drug Resistance.ahead of printhttp://doi.org/10.1089/mdr.2020.0218.correxcreative commons licenseOnline Ahead of Print:December 23, 2020PDF download